Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets)
Brand Names: Tilia Fe
Methodology & AI Transparency ⓘ
Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: FDA DailyMed monograph 2025-09-08 designates Tilia Fe (NDC 51862-896, 75907-086, registered by Mayne Pharma Inc.) as a prescription brand-name fda prescription therapeutic agent formulation of Ndac and Ee Tablets and Ferrous Fumarate Tablets.
- 2 Real-world patient consensus: Commercial Tilia Fe monograph (Kit) cross-indexed with generic Ndac and Ee Tablets and Ferrous Fumarate Tablets for therapeutic equivalence review.
- 3 Typical cash cost range: Public pharmacy ledger: $61.34 low cash benchmark vs. $162.55 chain retail average ($0.7339/unit CMS NADAC).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets) include nausea (9.2%), headache (8.5%), dizziness (6.9%).
Ask our AI Specialists anything about Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets)
Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets) Mechanism, CYP450 Pathways & DailyMed Monograph
FDA DailyMed monograph 2025-09-08 designates Tilia Fe (NDC 51862-896, 75907-086, registered by Mayne Pharma Inc.) as a prescription brand-name fda prescription therapeutic agent formulation of Ndac and Ee Tablets and Ferrous Fumarate Tablets. Supplied across Kit; Response-guided Ndac and Ee Tablets and Ferrous Fumarate Tablets dose modification under follow-up, Tilia Fe is utilized in Tilia Fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
Clinical pharmacology for Tilia Fe is driven by Ndac and Ee Tablets and Ferrous Fumarate Tablets acting within fda prescription therapeutic agent signaling cascades with class-characteristic hepatorenal disposition. Distributed across Kit; Response-guided Ndac and Ee Tablets and Ferrous Fumarate Tablets dose modification under follow-up (NDC 51862-896, 75907-086; registered by Mayne Pharma Inc.), the branded formulation calibrates systemic exposure and patient adherence, with public 30-day cash benchmarks ranging from $61.34 to $162.55.
Following administration (Kit), Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets) achieves Consistent 59%–71% gastrointestinal absorption profile for Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets) bioavailability and cmax attained 2–3 hours post-administration of tilia fe (ndac and ee tablets and ferrous fumarate tablets) onset, governed by a Elimination kinetics span 8 to 20 hours per Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets) clinical pharmacology terminal half-life through systemic clearance of tilia fe (ndac and ee tablets and ferrous fumarate tablets) integrates hepatic phase ii conjugation with renal filtration.
Before initiating Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets) at Kit, clinical safety checklists rule out history of severe allergic sensitivity to tilia fe (ndac and ee tablets and ferrous fumarate tablets) active moiety or formulation vehicle; acute clinical instability or interacting polypharmacy excluded under 2025-09-08 ndac and ee tablets and ferrous fumarate tablets labeling. Logged tolerability patterns center on nausea (9.2% of reports), headache (8.5% of reports), dizziness (6.9% of reports).
Verify medication reconciliation lists so Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets) is not inadvertently duplicated with another fda prescription therapeutic agent.
Botanical enzyme modulators may alter oral first-pass exposure of Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- History of severe allergic sensitivity to Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets) active moiety or formulation vehicle
- Acute clinical instability or interacting polypharmacy excluded under 2025-09-08 Ndac and Ee Tablets and Ferrous Fumarate Tablets labeling
Logged Side-Effect Incidence (16 Reports)
Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in: What a 538-Participant Study Found A single dose of rimegepant 75 mg rimegepant was effective for the acute treatment of migraine in adults living in China, with safety and tolerability similar to placebo. The journal of headache and pain • 2024-04-16 • Phase III Randomized Trial | N = 538 | 93/100 | PMID 38627638 ↗ |
| New Insights on Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy: What a 742-Participant Study Found HDM SLIT-tablet AIT is efficacious in HDM-sensitised asthma subjects with a genetic asthma predisposition and/or an underlying T2 endotype. Thorax • 2024-03-15 • Phase III Randomized Trial | N = 742 | 93/100 | PMID 38160049 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Budesonide Orodispersible Tablets for Eosinophilic Clinical and histologic full symptom relief of EoE could be maintained with BOT in a large majority of patients for up to 96 weeks, and for up to 144 weeks in patients with uninterrupted BOT therapy across all trials. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2025-11-15 • Phase III Randomized Trial | N = 186 | 88/100 | PMID 39694205 ↗ |
| Can This Approach Help? Inside the Latest Research on SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic As a result of the coronavirus disease 2019 pandemic, asthma exacerbation rates were much lower than expected, contributing to the primary endpoint not being met. Allergy • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41064908 ↗ |
| Can This Approach Help? Inside the Latest Research on Similar Efficacy of Mesalazine in Adult and Older Adult Ulcerative Colitis We observed similar efficacy of mesalazine in adult and older adult UC patients. Inflammatory bowel diseases • 2025-04-10 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38902993 ↗ |
Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.7339/unit (~$22.02/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $162.55 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $61.34 / mo | View logs ↓ |
Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets) RxNorm Concept ID | 1359130 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.7339 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $162.55 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $61.34 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 88.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets): FDA labeling (2025-09-08, NDC 51862-896), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Tilia Fe (Ndac and Ee Tablets and Ferrous Fumarate Tablets) community threads and patient logs by age, biological sex, dosage, and treatment duration.